StreetInsider.com News Articles

Longeveron HLHS trial misses primary endpoint, explores options

Wed, 16 Sep 2026 17:27:33 -0400

Longeveron Inc. (NASDAQ: LGVN) announced that its ELPIS II Phase 2b clinical trial evaluating laromestrocel as an adjunct treatment for hypoplastic left heart syndrome (HLHS) did not meet its primary efficacy endpoint.

The trial, which enrolled 40 infants, measured change from baseline in right ventricular ejection fraction (RVEF) at 12 months. In the intent-to-treat population, the least-squares mean difference between treatment groups was −0.7 percentage points (95% CI: −7.3 to 5.9; p=0.8336).

Exploratory as-treated analyses showed no deaths among laromestrocel-treated patients over 12 months, compared to one death in the control group. Adjudicated major adverse cardiovascular events were approximately 31% fewer in

Longeveron HLHS trial misses primary endpoint, explores options

Wed, 16 Sep 2026 17:27:33 -0400

Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Wed, 16 Sep 2026 17:27:00 -0400

Company Announces Exploration of All Options to Maximize Shareholder Value

The top line results showed that the ELPIS II trial did not meet its primary endpoint of improvement in right ventricular ejection fraction (RVEF) at month 12, but there were exploratory clinical endpoints that the Company is continuing to analyze and plans to discuss with the FDA to determine a potential path forward in HLHS
Laromestrocel has maintained what Longeveron believes is a favorable safety and tolerability profile consistent with prior clinical trials, now with 644 patients treated across Longeveron's multiple clinical programs, and has shown potential efficacy

Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Wed, 16 Sep 2026 17:27:00 -0400

Company Announces Exploration of All Options to Maximize Shareholder Value

The top line results showed that the ELPIS II trial did not meet its primary endpoint of improvement in right ventricular ejection fraction (RVEF) at month 12, but there were exploratory clinical endpoints that the Company is continuing to analyze and plans to discuss with the FDA to determine a potential path forward in HLHS
Laromestrocel has maintained what Longeveron believes is a favorable safety and tolerability profile consistent with prior clinical trials, now with 644 patients treated across Longeveron's multiple clinical programs, and has shown potential efficacy

Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Wed, 16 Sep 2026 17:27:00 -0400

Company Announces Exploration of All Options to Maximize Shareholder Value

The top line results showed that the ELPIS II trial did not meet its primary endpoint of improvement in right ventricular ejection fraction (RVEF) at month 12, but there were exploratory clinical endpoints that the Company is continuing to analyze and plans to discuss with the FDA to determine a potential path forward in HLHS
Laromestrocel has maintained what Longeveron believes is a favorable safety and tolerability profile consistent with prior clinical trials, now with 644 patients treated across Longeveron's multiple clinical programs, and has shown potential efficacy

Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Wed, 16 Sep 2026 17:27:00 -0400

Company Announces Exploration of All Options to Maximize Shareholder Value

The top line results showed that the ELPIS II trial did not meet its primary endpoint of improvement in right ventricular ejection fraction (RVEF) at month 12, but there were exploratory clinical endpoints that the Company is continuing to analyze and plans to discuss with the FDA to determine a potential path forward in HLHS
Laromestrocel has maintained what Longeveron believes is a favorable safety and tolerability profile consistent with prior clinical trials, now with 644 patients treated across Longeveron's multiple clinical programs, and has shown potential efficacy

Longeveron sets 1-for-10 reverse stock split effective Aug. 26

Mon, 24 Aug 2026 16:05:17 -0400

Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company, announced a 1-for-10 reverse stock split of its Class A and Class B common stock, effective at 11:59 p.m. Eastern Time on Aug. 26, 2026. The stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market at the opening of trading on Aug. 27, 2026, under the existing ticker symbol "LGVN" and a new CUSIP number 54303L 302.

The reverse split was approved by stockholders at the company's annual meeting on July 1, 2026, and by the board of directors on July 31, 2026. The company stated the

Longeveron sets 1-for-10 reverse stock split effective Aug. 26

Mon, 24 Aug 2026 16:05:17 -0400

Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company, announced a 1-for-10 reverse stock split of its Class A and Class B common stock, effective at 11:59 p.m. Eastern Time on Aug. 26, 2026. The stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market at the opening of trading on Aug. 27, 2026, under the existing ticker symbol "LGVN" and a new CUSIP number 54303L 302.

The reverse split was approved by stockholders at the company's annual meeting on July 1, 2026, and by the board of directors on July 31, 2026. The company stated the

Longeveron sets 1-for-10 reverse stock split effective Aug. 26

Mon, 24 Aug 2026 16:05:17 -0400

Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company, announced a 1-for-10 reverse stock split of its Class A and Class B common stock, effective at 11:59 p.m. Eastern Time on Aug. 26, 2026. The stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market at the opening of trading on Aug. 27, 2026, under the existing ticker symbol "LGVN" and a new CUSIP number 54303L 302.

The reverse split was approved by stockholders at the company's annual meeting on July 1, 2026, and by the board of directors on July 31, 2026. The company stated the

Longeveron sets 1-for-10 reverse stock split effective Aug. 26

Mon, 24 Aug 2026 16:05:17 -0400

Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company, announced a 1-for-10 reverse stock split of its Class A and Class B common stock, effective at 11:59 p.m. Eastern Time on Aug. 26, 2026. The stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market at the opening of trading on Aug. 27, 2026, under the existing ticker symbol "LGVN" and a new CUSIP number 54303L 302.

The reverse split was approved by stockholders at the company's annual meeting on July 1, 2026, and by the board of directors on July 31, 2026. The company stated the

Longeveron sets 1-for-10 reverse stock split effective Aug. 26

Mon, 24 Aug 2026 16:05:17 -0400

Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company, announced a 1-for-10 reverse stock split of its Class A and Class B common stock, effective at 11:59 p.m. Eastern Time on Aug. 26, 2026. The stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market at the opening of trading on Aug. 27, 2026, under the existing ticker symbol "LGVN" and a new CUSIP number 54303L 302.

The reverse split was approved by stockholders at the company's annual meeting on July 1, 2026, and by the board of directors on July 31, 2026. The company stated the

Longeveron Announces 1-for-10 Reverse Stock Split

Mon, 24 Aug 2026 16:05:00 -0400

MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will undertake a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (collectively, the “Common Stock”) (the “2026 Reverse Split”). The 2026 Reverse Split was previously approved by the Company’s stockholders at the Company’s annual meeting held on July 1, 2026 and the Company’s Board

Longeveron Announces 1-for-10 Reverse Stock Split

Mon, 24 Aug 2026 16:05:00 -0400

MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will undertake a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (collectively, the “Common Stock”) (the “2026 Reverse Split”). The 2026 Reverse Split was previously approved by the Company’s stockholders at the Company’s annual meeting held on July 1, 2026 and the Company’s Board

Longeveron Announces 1-for-10 Reverse Stock Split

Mon, 24 Aug 2026 16:05:00 -0400

MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will undertake a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (collectively, the “Common Stock”) (the “2026 Reverse Split”). The 2026 Reverse Split was previously approved by the Company’s stockholders at the Company’s annual meeting held on July 1, 2026 and the Company’s Board

Longeveron Announces 1-for-10 Reverse Stock Split

Mon, 24 Aug 2026 16:05:00 -0400

MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will undertake a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (collectively, the “Common Stock”) (the “2026 Reverse Split”). The 2026 Reverse Split was previously approved by the Company’s stockholders at the Company’s annual meeting held on July 1, 2026 and the Company’s Board

Longeveron Announces 1-for-10 Reverse Stock Split

Mon, 24 Aug 2026 16:05:00 -0400

MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will undertake a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (collectively, the “Common Stock”) (the “2026 Reverse Split”). The 2026 Reverse Split was previously approved by the Company’s stockholders at the Company’s annual meeting held on July 1, 2026 and the Company’s Board

Longeveron Announces 1-for-10 Reverse Stock Split

Mon, 24 Aug 2026 16:05:00 -0400

MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will undertake a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (collectively, the “Common Stock”) (the “2026 Reverse Split”). The 2026 Reverse Split was previously approved by the Company’s stockholders at the Company’s annual meeting held on July 1, 2026 and the Company’s Board

Longeveron Announces 1-for-10 Reverse Stock Split

Mon, 24 Aug 2026 16:05:00 -0400

MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will undertake a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (collectively, the “Common Stock”) (the “2026 Reverse Split”). The 2026 Reverse Split was previously approved by the Company’s stockholders at the Company’s annual meeting held on July 1, 2026 and the Company’s Board

Longeveron Announces 1-for-10 Reverse Stock Split

Mon, 24 Aug 2026 16:05:00 -0400

MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will undertake a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (collectively, the “Common Stock”) (the “2026 Reverse Split”). The 2026 Reverse Split was previously approved by the Company’s stockholders at the Company’s annual meeting held on July 1, 2026 and the Company’s Board

Longeveron Announces 1-for-10 Reverse Stock Split

Mon, 24 Aug 2026 16:05:00 -0400

MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will undertake a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (collectively, the “Common Stock”) (the “2026 Reverse Split”). The 2026 Reverse Split was previously approved by the Company’s stockholders at the Company’s annual meeting held on July 1, 2026 and the Company’s Board

Longeveron Announces 1-for-10 Reverse Stock Split

Mon, 24 Aug 2026 16:05:00 -0400

MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will undertake a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (collectively, the “Common Stock”) (the “2026 Reverse Split”). The 2026 Reverse Split was previously approved by the Company’s stockholders at the Company’s annual meeting held on July 1, 2026 and the Company’s Board

Longeveron names Nirav Jhaveri as CFO

Wed, 19 Aug 2026 16:05:16 -0400

Longeveron Inc. (NASDAQ: LGVN) has appointed Nirav Jhaveri as chief financial officer, principal financial officer, and principal accounting officer, according to a company statement.

Jhaveri succeeds Marie Washburn, who had served as interim CFO following the retirement of the prior CFO. Washburn will return to her role as corporate controller.

Jhaveri holds more than 25 years of experience in capital markets, corporate finance, business development, and investor relations, including over 15 years in the biotech sector. He previously served as CFO at Opus Genetics (NASDAQ: IRD), Insilico Medicine (HKEX: 3696.HK), and Journey Medical Corporation (NASDAQ: DERM). Earlier in his career, he held

Longeveron names Nirav Jhaveri as CFO

Wed, 19 Aug 2026 16:05:16 -0400

Longeveron Inc. (NASDAQ: LGVN) has appointed Nirav Jhaveri as chief financial officer, principal financial officer, and principal accounting officer, according to a company statement.

Jhaveri succeeds Marie Washburn, who had served as interim CFO following the retirement of the prior CFO. Washburn will return to her role as corporate controller.

Jhaveri holds more than 25 years of experience in capital markets, corporate finance, business development, and investor relations, including over 15 years in the biotech sector. He previously served as CFO at Opus Genetics (NASDAQ: IRD), Insilico Medicine (HKEX: 3696.HK), and Journey Medical Corporation (NASDAQ: DERM). Earlier in his career, he held

Longeveron names Nirav Jhaveri as CFO

Wed, 19 Aug 2026 16:05:16 -0400

Longeveron Inc. (NASDAQ: LGVN) has appointed Nirav Jhaveri as chief financial officer, principal financial officer, and principal accounting officer, according to a company statement.

Jhaveri succeeds Marie Washburn, who had served as interim CFO following the retirement of the prior CFO. Washburn will return to her role as corporate controller.

Jhaveri holds more than 25 years of experience in capital markets, corporate finance, business development, and investor relations, including over 15 years in the biotech sector. He previously served as CFO at Opus Genetics (NASDAQ: IRD), Insilico Medicine (HKEX: 3696.HK), and Journey Medical Corporation (NASDAQ: DERM). Earlier in his career, he held

Longeveron names Nirav Jhaveri as CFO

Wed, 19 Aug 2026 16:05:16 -0400

Longeveron Inc. (NASDAQ: LGVN) has appointed Nirav Jhaveri as chief financial officer, principal financial officer, and principal accounting officer, according to a company statement.

Jhaveri succeeds Marie Washburn, who had served as interim CFO following the retirement of the prior CFO. Washburn will return to her role as corporate controller.

Jhaveri holds more than 25 years of experience in capital markets, corporate finance, business development, and investor relations, including over 15 years in the biotech sector. He previously served as CFO at Opus Genetics (NASDAQ: IRD), Insilico Medicine (HKEX: 3696.HK), and Journey Medical Corporation (NASDAQ: DERM). Earlier in his career, he held